NeuClone Pharmaceuticals Ltd
https://neuclone.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From NeuClone Pharmaceuticals Ltd
Deal Watch: Bristol Adds To Vaccines ‘Repertoire,’ Takes ‘Scenic’ View Of Cellular Pathways
BMS partners with Repertoire and Scenic, plus deals involving: G1/Pepper, Harmony/Epygenix, Biodexa/Emtora, Regeneron/Mammoth, Vertex/Treefrog and Immedica/KKR/Impilo.
History Repeats: Will US Stelara Settlements Follow Humira’s Lead?
Hopes are rising that Johnson & Johnson will be able to emulate AbbVie’s success in delaying US biosimilar competition to its top-selling Humira by using a similar settlement strategy with its anti-IL12/IL23 blockbuster Stelara.
NeuClone Reveals Rivals To Opdivo And Keytruda
Australia’s NeuClone has revealed further details of its pipeline, offering an update that includes a glimpse at two further biosimilar projects that are in active development.
Company Information
- Industry
- Biotechnology
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice